It was the '80s — the hair was big, life was large, and Aussie Rules were dirty words in Queensland. One man with a lot of cash to splash would change that.

It's a difficult time for all footy clubs and everyone involved with suspended seasons — but if you're a holder of a club membership who wants a refund, you might be left disappointed.

You might forgive the ARLC chairman his belligerence if the cost of careless statements and premature season recommencement dates could not now literally be measured in human lives, writes Richard Hinds.

The NRL has a number of crucial questions it must answer if it wants to restart its premiership season on May 28 as planned following the coronavirus-forced suspension of the competition, writes David Mark.

Australia's elite sportspeople wronged by dud selection calls or dodgy doping violations are set to chase justice in a new legal arena.

NRL clubs will be able to resume training from May 4 as the competition charges towards its planned restart three weeks later.

Flattering comparisons with other leading sports officials have also helped elevate the ARL chairman's current status as the can-do man of Australian sport, but as Richard Hinds asks, is he about to make a huge mistake?

Victoria Police suspends an officer over an "unlawful and criminal" privacy breach after images were released of former North Melbourne coach Dean Laidley in custody inside a police station.

Chinese swimmer Sun Yang has reportedly appealed against his eight-year suspension for doping — it is the three-time Olympic champion's last hope to remain eligible for a fourth Games in Tokyo.

Cycling's governing body responds to the coronavirus pandemic, announcing a jam-packed 100-day schedule with a string of major races — including two Grand Tours — in October alone.

It is one of south-west Victoria's biggest money-spinning events, attracting thousands of partying racegoers — but the local economy came in last when this year's May Racing Carnival ran with no spectators.

With coronavirus putting a pause on the AFL season, Melbourne's Marty Hore and Collingwood's Flynn Appleby return to their family dairy farms.

On the anniversary of the birth of the Works Progress Administration, it's worth asking what a post-COVID Federal Writers Project might look like.

Amy Jo Burns' novel, "Shiner," illuminates an Appalachia whose men "pray for God to show Himself while our wives wash their husbands' underpants."

Billie Eilish will co-host an Apple Music radio program with her father, Patrick O'Connell, called "me & dad radio."

Washington state fruit growers say that a ban on bunk beds in farmworker housing would cut their seasonal work force in half, likely leading to food shortages and price hikes.

The airport has been granted permission to appeal a block on its expansion plans

AppLovin turns mobile into the medium of choice for brands by using data gathered across screens to deliver dynamic mobile ads for consumers.

A global services provider, helping companies power their business with mobile, social and cloud technology from salesforce.com, Google, Workday and CSOD

Michael Rubin is applauding Chris Pratt and David Blaine for going above and beyond with the All In Challenge, and says it's beautiful to see celebs commit their time to the cause. The Philadelphia 76ers partner, and creator of the Challenge,…

Roche’s antibody test for Covid-19 has been given the CE mark and has been issued Emergency Use Authorisation from the US Food and Drug Administration.

New era for lymphoma, leukemia, possibly other cancers

Agency moves toward more accelerated reviews

The programme is expected to roll out nationally mid-May

The approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option

As cancer research reveals the genetic basis of the disease, pharmaceutical companies are pursuing targeted therapies that address certain groups of patients. One such drug from Novartis won FDA approval Wednesday, making it the first therapy cleared by the agency to treat patients whose non-small cell lung cancer (NSCLC) carries a certain genetic mutation. The […]

The Royal College of Physicians (RCP) has appointed Dr Wajid Hussain as its new clinical director for digital health.

Dr Hussain, a cardiologist and cardiac electrophysicist at the Royal Brompton and Harefield NHS Trust, has a demonstrated interest in IT and health.

While he currently represents the views of clinicians on the Trust’s IT committee, Dr Hussain completed a Diploma in Digital Health Leadership at the NHS Digital Academy last year. He is also currently studying for a Master’s in Digital Health leadership at Imperial College London.

read more

Cerevel Therapeutics, a pharmaceutical company dedicated to treating neurological diseases, has appointed renowned biotechnology leader Tony Coles as Chief Executive Officer (CEO).

read more

Immunotherapy-focused pharmaceutical company Midatech Pharma has appointed Stephen Stamp as Chief Financial Officer (CFO) with immediate effect.

He will be replacing Nick Robbins-Cherry, who has stepped down after five years since joining in 2014. Robbins will nevertheless remain at Midatech until October to facilitate Stamp’s handover in an orderly fashion.

Stamp has most recently served as CEO of pharmaceutical firm Ergomed for two years, stepping down in January citing health reasons. Prior to this he was CFO at Ergomed for a year beginning in 2016.

read more

The General Pharmaceutical Council has appointed Laura Fraser, former clinical fellow for the Scottish Chief Pharmaceutical Officer as the new Director for Scotland.

Fraser has held leadership roles in community pharmacy across Scotland including board member of Community Pharmacy Scotland. She has also worked for the Scottish Government as Clinical Leadership Fellow. Prior to her position as board member she was area and regional manager for nearly nine years.

read more

Gilead Sciences have announced that Merdad Parsey will join the company as Chief Medical Officer, effective November 1st.

Dr Parsey will be responsible for and oversee the company’s global clinical development and medical affairs organisations – reporting directly to Daniel O’Day, Gilead’s Chairman and Chief Executive Officer.

read more

Gilead Sciences have announced that Andrew Dickinson has been appointed as Chief Financial Officer (CFO) effective 1 November.

Dickinson currently serves as the company’s Executive Vice President of Corporate Development and Strategy and in his new role will become part of a senior leadership team reporting directly to Chairman and Chief Executive Officer Daniel O’Day.

read more

Saniona has announced that Rami Levin will take over as the Chief Executive Officer of the company as it seeks to transition into a fully-fledge biopharmaceuticals company, with a focus on rare diseases.

Levin was appointed by the Board of Directors and the company’s founders. His appointment takes immediate effect.

read more

Ipsen has named Dr Steven Hildemann as its new Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance.

In his new role, which begins on 1 March 2020 and will be based in Paris, he will report directly to Ipsen CEO Aymeric Le Chatelier. His remit will include the provision of medical strategy to the company’s scientific, clinical and business teams, while also working in tandem with its R&D operations to design and direct clinical trials efforts to generation of post-launch data.

read more

AI drug discovery firm Exscientia has announced the appointment of Dr David Hallett as its Chief Operating Officer and Head of Drug Discovery.

Bringing 20 years of experience to the role, Dr Hallett’s primary remit will see him take responsibility for the company’s entire drug discovery portfolio, as well as managing pharma collaborations, joint ventures and pipeline projects. He will report to Exscientia Founder and CEO Professor Andrew Hopkins.

read more

Nordic Nanovector has appointed Dr Lars Nieba as the interim Chief Executive Officer. He is currently the company’s Chief Technology Officer and replaces Eduardo Bravo who as of today has left Nordic to pursue other career opportunities.

read more

Genmab has announced the establishment of the new position of Chief Operating Officer at the company, and has furthermore named Anthony Mancini to the post. In this new role, he will oversee the company’s commercial strategies, including corporate development, business development and information technology functions

read more

StrideBio have announced the appointment of Maritza McIntyre Ph.D., as its first Chief Development Officer.

The newly created role will see Dr McIntyre oversea the translational development of the company’s research-stage gene therapy programs. This includes regulatory filings, initiating early clinical studies and starting Investigational New Drug enabling preclinical studies.

read more

Dr Lisa von Moltke has left Aklermes and has joined Seres Therapeutics as its new Chief Medical Officer.

Chief Executive Officer at Seres, Eric Shaff, said Seres will benefit from von Moltke’s “extensive experience directing successful development programs, leading clinical teams, and interacting with regulatory agencies across multiple areas of medicine.”

read more

In this video explainer, Christopher Robertson discusses the Right to Try Act and off-label use of pharmaceuticals with Alison Bateman-House.

The post Access to Drugs Before FDA Approval: Video Explainer with Christopher Robertson appeared first on Bill of Health.

Developing, executing and overseeing clinical trials is a complex process. Yet it is essential to gain reliable evidence from clinical trials to...

Sanofi’s MedQuadfi Meningococcal Conjugate Vaccine has scored FDA approval for the prevention of invasive meningococcal disease, becoming the first and only product available in the US for this indication in patients of at least two years old.

NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which rows back on the Institute’s decision to reject the drug last year.

Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients.

Gilead’s antiviral therapy remdesivir has shown tentatively promising efficacy in the race to find an effective treatment for COVID-19, one of the only therapies to do so at this early stage of the pandemic. Now, the FDA has invoked its Emergency Use Authorization powers to approve the drug for the treatment of patients hospitalised with the novel coronavirus.

The NHS’s coronavirus contract tracing app has been published to Apple and Google’s app stores with council staff and healthcare workers being invited to download it on the Isle of Wight today.

The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular death and hospitalisation in adult patients with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.

The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta for the first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have a mutation that leads to MET exon 14 skipping (METex14), regardless of whether they have previously received any type of treatment.